Advice
in the absence of a submission from the holder of the marketing authorisation:
givosiran (Givlaari®) is not recommended for use within NHSScotland.
Indication under review: Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice616KB (PDF)
Medicine details
- Medicine name:
- givosiran (Givlaari)
- SMC ID:
- SMC2470
- Indication:
Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.
- Pharmaceutical company
- Alnylam Pharmaceuticals
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 March 2022